Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells $161,572.52 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 2,084 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $77.53, for a total transaction of $161,572.52. Following the completion of the transaction, the senior vice president owned 50,993 shares of the company’s stock, valued at approximately $3,953,487.29. The trade was a 3.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Krista Davis also recently made the following trade(s):

• On Friday, February 20th, Krista Davis sold 1,730 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $77.99, for a total value of $134,922.70.
• On Thursday, December 18th, Krista Davis sold 1,622 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.40, for a total value of $133,652.80.

ANI Pharmaceuticals Trading Down 0.5%

Shares of NASDAQ:ANIP opened at $76.30 on Thursday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. ANI Pharmaceuticals, Inc. has a 1 year low of $54.10 and a 1 year high of $99.50. The company has a market cap of $1.71 billion, a P/E ratio of 46.81 and a beta of 0.50. The stock’s fifty day moving average price is $80.48 and its 200-day moving average price is $86.53.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ANIP shares. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Barclays initiated coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target on the stock. Finally, Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $103.43.

Key ANI Pharmaceuticals News

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI will present at three healthcare/investor conferences in early March (Raymond James, Leerink, Barclays), increasing management access to institutional investors and providing fresh disclosure via webcasts. Conference Announcement
• Positive Sentiment: Wall Street coverage remains constructive: recent analyst activity leaves ANIP with a consensus near “Moderate Buy” and several price targets well above the current level (median targets cited above $100), which can support upward pressure if analysts reiterate or raise targets. Analyst Rating
• Neutral Sentiment: Short‑interest postings for late February appear to report zero shares (and show NaN increases), which is likely a reporting error and does not indicate elevated short pressure or covering demand in the near term.
• Negative Sentiment: Insider selling has been active: SVP Krista Davis sold multiple blocks (most recently ~1,730 shares at ~ $78) and Christopher Mutz also sold shares — continued insider dispositions may be viewed negatively by the market, adding near‑term selling pressure. Krista Davis Sale Christopher Mutz Sale

Institutional Investors Weigh In On ANI Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Hantz Financial Services Inc. raised its holdings in ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 237 shares during the period. Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals in the first quarter worth about $28,000. Caitong International Asset Management Co. Ltd raised its stake in shares of ANI Pharmaceuticals by 4,636.4% in the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 510 shares during the period. Newbridge Financial Services Group Inc. raised its stake in shares of ANI Pharmaceuticals by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock worth $39,000 after buying an additional 400 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $48,000. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.